why choose us

Clinical Trials Search

Showing 9,340 of 132,656 result(s)
Phase 1 Study to Assess Safety and Efficacy of ANG003

Status: Completed

Condition: Exocrine Pancreatic Insufficiency

Interventions: To evaluate four possible combinations of lipase, protease and amylase.

Date: 2023-08-09

Intervention to Reduce Safety Behaviors

Status: NOT_YET_RECRUITING

Condition: Social Anxiety

Interventions: Participant will receive text message every other day during active phase (30days) via ANNIE text messaging app related to the safety behaviors they i

Date: 2023-08-09

Financial Incentives and Recruitment to the APT Webstudy

Status: Completed

Condition: Alzheimer Disease

Interventions: Small financial incentive or prize incentive

Date: 2023-08-09

Cleaner Air for Lower Cardiometabolic Risk

Status: NOT_YET_RECRUITING

Condition: PreDiabetes

Interventions: A commercially available PAC with a true HEPA filter will be used.
Unit will be placed in the bedroom and used continuously (24 hours;day) f

Date: 2023-08-09

CONNEQT Pulse Validation Study

Status: Completed

Condition: Pregnancy Related

Interventions: Serial blood pressure measurements to compare reference auscultatory sphygmomanometer to CONNEQT Pulse according to ISO 81060-2.

Date: 2023-08-08

Hyaluronidase Via LADD Scleroderma-induced Microstomia

Status: NOT_YET_RECRUITING

Condition: Microstomia

Interventions: hyaluronidase injection is used during fluid administration under the skin to help achieve hydration, to increase the dispersion and absorption of oth

Date: 2023-08-08

Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection

Status: Completed

Condition: Vaccine Reaction

Interventions: Venezuelan Equine Encephalitis DNA Vaccine Candidate

Date: 2023-08-08

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

Status: NOT_YET_RECRUITING

Condition: Opioid-Related Disorders

Interventions: Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an

Date: 2023-08-08